Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25331385 | 0.97 | CRBN (0.56) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25428553 | 0.92 | CRBN (0.55) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30144393 | 0.89 | MAPT (0.52) | CRBNDDB1MAPTALDH1A1CHRM2 | |
| SCHEMBL20985258 | 0.89 | MAPT (0.52) | CRBNDDB1MAPTALDH1A1CHRM2 | |
| SCHEMBL30144472 | 0.89 | MAPT (0.52) | CRBNDDB1MAPTALDH1A1CHRM2 | |
| SCHEMBL30144174 | 0.89 | MAPT (0.52) | CRBNDDB1MAPTALDH1A1CHRM2 | |
| SCHEMBL23860180 | 0.89 | MAPT (0.52) | CRBNDDB1MAPTALDH1A1CHRM2 | |
| SCHEMBL23860136 | 0.89 | MAPT (0.52) | CRBNDDB1MAPTALDH1A1CHRM2 | |
| SCHEMBL20985419 | 0.89 | MAPT (0.52) | CRBNDDB1MAPTALDH1A1CHRM2 | |
| SCHEMBL30144140 | 0.89 | MAPT (0.52) | CRBNDDB1MAPTALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220265834-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2022-08-25 | — | — | US | disclosed |
| EP-3972966-A1 | BCL-2 PROTEIN INHIBITORS | Recurium IP Holdings, LLC (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114144411-A | BCL-2 protein inhibitors | 里科瑞尔姆IP控股有限责任公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265834-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | CRBN 317/4885DDB1 198/4885MAPT 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.